EP0566245A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Intraluminal stent
Assignee: Medtronic Inc
•
Filing: 1993-03-15
•
Granted: —
•
Expires: 2013-03-15
Abstract
Abstract An intraluminal stent comprising fibrin is capable of reducing the incidence of restenosis at the site of vascular injury such as that produced by an angioplasty procedure.
Inventors
- 👤 Robert S. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-22 23:26
CPC Classifications
A; A61; A61L; A61L31/00; A61L31/14; A61L31/16; A61F; A61F2/00; A61F2/82; A61L31/04; A61L31/041; A61L31/043; A61L31/046; A61L31/047; A61L31/08; A61L31/10; A61L31/12; A61L31/125; A61L31/128; A61F2/0077; A61F2240/00; A61F2240/001; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/236; A61L2300/252; A61L2300/40; A61L2300/416; A61L2300/42; A61L2300/60; A61L2300/62; A61L2300/622; Y; Y10; Y10S; Y10S623/00; Y10S623/901
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
7 words
An intraluminal stent (20) comprising fibrin (24).
Claim 2
Dependent Claim
7 words
An intraluminal stent (20) comprising fibrin (24).
Claim 3
Dependent Claim
16 words
A stent as claimed in claim 1 having an underlying structure (22) of a deformable material.
Claim 4
Dependent Claim
13 words
Astent as claimed in claim 2 wherein said deformable material is a metal.
Claim 5
Dependent Claim
20 words
A stent as claimed in either of claims 2 and 3 wherein said deformable material is embedded in the fibrin.
Claim 6
Dependent Claim
25 words
A stent (30) as claimed in either of claims 2 and 3 wherein the fibrin is in a film (32) on said deformable material (34).
Claim 7
Dependent Claim
21 words
A stent as claimed in any one of claims 1 to 5 wherein the fibrin is intermixed with a polymeric material.
Claim 8
Dependent Claim
22 words
A stent as claimed in any one of claims 1 to 6comprising a fibrin in which residual coagulating protein has been neutralized.
Claim 9
Dependent Claim
19 words
A stent as claimed in any one of claims 1 to 7 wherein the fibrin contains a therapeutic substance.
Claim 10
Dependent Claim
15 words
A stent as claimed in claim 8 wherein said therapeutic substance is incorporated in microcapsules.
Claim 11
Dependent Claim
27 words
A stent as claimed in either of claims 8 and 9 wherein said therapeutic substance is selected from anticoagulant drugs, antiplatelet drugs, antimetabolite drugs and antimitotic drugs.
Claim 12
Dependent Claim
41 words
A stent assembly comprising a stent (20) as claimed in anyone of claims 1 to 10 further comprising a catheter (10) having a balloon (15) at a distal end thereof, the stent being mounted on the outside surface of said balloon.
Claim 13
Independent Claim
16 words
A method for making an intraluminal stent, the method comprising depositing fibrin on a stent substrate.
Claim 14
Independent Claim
16 words
A method for making an intraluminal stent, the method comprising depositing fibrin on a stent substrate.
Claim 15
Dependent Claim
14 words
A method as claimed in claim 12 wherein fibrin is polymerized on said substrate.
Claim 16
Dependent Claim
30 words
A method as claimed in claim 13 wherein polymerization is effected by applying to said substrate successively (a) a solution of fibrinogen and (b) a solution of a fibrinogen-coagulating protein.
Claim 17
Dependent Claim
15 words
Amethod as claimed in claim 14further comprising neutralizing the coagulating effect of residual coagulating protein.
Claim 18
Dependent Claim
18 words
A method as claimed in claim 15 wherein neutralization is effected by the addition of a thrombin inhibitor.
Claim 19
Independent Claim
23 words
A method as claimed in any one of claims 14 to 16 wherein the fibrinogen-coagulating protein is selected from thrombin, reptilase and ancrod.
Claim 20
Independent Claim
25 words
A method as claimed in any one of claims 13 to 17 further comprising the step of incubating the fibrin in a biological buffer solution.
Claim 21
Dependent Claim
16 words
A method as calimed in claim 12 wherein a fibrin preform is applied to said substrate.
Claim 22
Dependent Claim
13 words
A method as claimed in claim 19 wherein said preform is a film.
Claim 23
Independent Claim
22 words
A method as claimed in either of claims 19 and 20 wherein said preform is secured to said substrate with an adhesive.
Claim 24
Independent Claim
27 words
A method as claimed in any one of claims 12 to 21 further comprising the step of affixing the stent onto a distal end of a catheter.
Claim 25
Dependent Claim
23 words
A method as claimed in claim 22 wherein the catheter is a balloon catheter and the stent is affixed upon the balloon thereof.
Claim 26
Independent Claim
38 words
A method for making a intravascular device from fibrin comprising the steps of: (a) admixing fibrinogen with a coagulating protein to produce fibrin; (b) neutralizing the coagulating protein, and (c) incubating the fibrin in a biological buffer solution.
Claim 27
Independent Claim
38 words
A method for making a intravascular device from fibrin comprising the steps of: (a) admixing fibrinogen with a coagulating protein to produce fibrin; (b) neutralizing the coagulating protein, and (c) incubating the fibrin in a biological buffer solution.
Claim 28
Dependent Claim
24 words
A method as claimed in claim 24 wherein said coagulating protein is thrombin and a thrombin inhibitor is used for neutralizing the coagulating protein.
Claim 29
Dependent Claim
20 words
A method as claimed in claim 25 wherein said thrombin inhibitor is selected from hirudin and D-phenylalanyl-propyl-arginine chloromethyl ketone (PPACK).
Claim 30
Independent Claim
27 words
A method as claimed in any one of claims 18 and 24 to 26 wherein said biological buffer solution comprises blood serum buffered with 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES).
Claim 31
Dependent Claim
15 words
The use of fibrinogen orfibrin for the manufacture of means for use in combatting restenosis.
Claim 32
Dependent Claim
15 words
The use of fibrinogen orfibrin for the manufacture of means for use in combatting restenosis.
References Cited (Backward Citations)
EP0366564A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.